hVIVOOPORF +27.29%48 Return-on-Tangible-Asset is -19.35% as of Dec. 2025. GuruFocus rates OPORF with a GF Score™ of 48/100 and a GF Value™ of $0.60 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, hVIVO ranks worse than 60.93% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. hVIVO's annualizedNet Income for the quarter that ended in Dec. 2025 was $-15.75 Mil. hVIVO's average total tangible assets for the quarter that ended in Dec. 2025 was $81.41 Mil. Therefore, hVIVO's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -19.35%.
The historical rank and industry rank for hVIVO's Return-on-Tangible-Asset or its related term are showing as below:
OPORF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -180.84 Med: -5.36 Max: 26.22
Current: -8.82
During the past 13 years, hVIVO's highest Return-on-Tangible-Asset was 26.22%. The lowest was -180.84%. And the median was -5.36%.
OPORF's Return-on-Tangible-Asset is ranked worse than 60.93% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs OPORF: -8.82
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
hVIVO Return-on-Tangible-Asset Related Terms
hVIVO Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for hVIVO's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OPORF vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, hVIVO's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
hVIVO Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, hVIVO's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where hVIVO's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -19.35% mean?
hVIVO (OPORF) has a Return-on-Tangible-Asset of -19.35% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on hVIVO and its competitors. According to the industry distribution chart, hVIVO ranks #131 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 60.9%.
Is hVIVO's Return-on-Tangible-Asset too high?
hVIVO's current Return-on-Tangible-Asset is -19.35%. Based on the distribution chart, hVIVO ranks #131 out of 215 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, hVIVO has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does hVIVO's Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, hVIVO ranks #131 out of 215 companies for Return-on-Tangible-Asset. This places hVIVO in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on hVIVO and its competitors. hVIVO's current Return-on-Tangible-Asset is -19.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is hVIVO stock overvalued right now?
Based on GuruFocus' analysis, hVIVO (OPORF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.60, compared to a current price of $0.11 — trading 81.7% below its estimated fair value. The current Return-on-Tangible-Asset is -19.35%. hVIVO's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For hVIVO (OPORF), the current Return-on-Tangible-Asset is -19.35% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is hVIVO (OPORF) Overvalued in 2026?
Based on GuruFocus' analysis, hVIVO stock appears to be undervalued.
The current stock price of $0.11 is trading 81.7% below its estimated GF Value™ of $0.60.
GuruFocus considers hVIVO to be Possible Value Trap.
Key valuation signals for OPORF:
Return-on-Tangible-Asset: -19.35%
GF Value™: $0.60 vs. price of $0.11 (81.7% below fair value)
No single metric tells the full story. See the OPORF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
hVIVO PLC is a full-service early phase Contract Research Organisation (CRO). It delivers end-to-end clinical development services to a diverse and expanding client base. The group specialises in conducting human challenge trials across multiple infectious and respiratory indications. It also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its subsidiary, it provides early-phase clinical trial services and Early Drug Development Consulting and Biometry services to the biopharma sector. It provides development solutions from preclinical stages through Phase II trials, via FluCamp. Geographically, the company generates maximum revenue from Europe, followed by North America, the United Kingdom, and Asia.
48GF Score
Get the complete analysis for OPORF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPORF has been successfully added to your 
